WO2025104233 - INHIBITION OF PROSTAGLANDIN D2 RECEPTOR 1 AS MEANS FOR TREATING CANCER

National phase entry is expected:
Publication Number WO/2025/104233
Publication Date 22.05.2025
International Application No. PCT/EP2024/082474
International Filing Date 15.11.2024
Title [English] INHIBITION OF PROSTAGLANDIN D2 RECEPTOR 1 AS MEANS FOR TREATING CANCER [French] INHIBITION DU RÉCEPTEUR 1 DE LA PROSTAGLANDINE D2 EN TANT QUE MOYEN DE TRAITEMENT DU CANCER
Applicants ** VIB VZW Suzanne Tassierstraat 1 9052 Gent, BE KATHOLIEKE UNIVERSITEIT LEUVEN K.U.LEUVEN R&D Waaistraat 6 - bus 5105 3000 Leuven, BE
Inventors ** MAZZONE, Massimiliano c/o VIB-KU Leuven Center for Cancer Biology Campus Gasthuisberg Herestraat 49 3000 Leuven, BE TROTTA, Rosa c/o VIB-KU Leuven Center for Cancer Biology Campus Gasthuisberg Herestraat 49 3000 Leuven, BE
Priority Data 23210284.8  16.11.2023  EP
Application details
International Searching Authority
Translation

Recalculate

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country Stages Total
China Filing 1415
EPO Filing, Examination 5911
Japan Filing 565
South Korea Filing 578
USA Filing, Examination 3835
MasterCard Visa
Total: 12304
Abstract [English] The disclosure relates to the medical use of inhibitors of expression or function of the prostaglandin D2 receptor 1 in the treatment of cancer in general or more in particular in the treatment of cancer in which HPGDS is predominantly expressed by tumor-associated macrophages in the tumor micro-environment. The disclosure further relates to isolated immune cells in which prostaglandin D2 receptor 1 expression or function is inhibited, such as for medical use. [French] L'invention concerne l'utilisation médicale d'inhibiteurs de l'expression ou de la fonction du récepteur 1 de la prostaglandine D2 dans le traitement du cancer en général et plus particulièrement dans le traitement du cancer dans lequel HPGDS est principalement exprimé par des macrophages associés aux tumeurs dans le micro-environnement tumoral. L'invention concerne en outre des cellules immunitaires isolées dans lesquelles l'expression ou la fonction du récepteur 1 de la prostaglandine D2 est inhibée, par exemple pour une utilisation médicale.